Equities

Genovis AB

Genovis AB

Actions
  • Price (SEK)26.80
  • Today's Change0.05 / 0.19%
  • Shares traded93.92k
  • 1 Year change-43.28%
  • Beta1.7008
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 3 analysts offering 12 month price targets for Genovis AB have a median target of 34.00, with a high estimate of 52.00 and a low estimate of 30.00. The median estimate represents a 26.87% increase from the last price of 26.80.
High94.0%52.00
Med26.9%34.00
Low11.9%30.00

Earnings history & estimates in SEK

On Nov 08, 2024, Genovis AB reported 3rd quarter 2024 earnings of 0.21 per share. This result exceeded the 0.09 consensus of the 2 analysts covering the company and exceeded last year's 3rd quarter results by 0.16.
The next earnings announcement is expected on Feb 16, 2025.
Average growth rate+257.89%
Genovis AB reported annual 2023 earnings of 0.94 per share on Feb 15, 2024.
Average growth rate+171.47%
More ▼

Revenue history & estimates in SEK

Genovis AB (publ.) had 3rd quarter 2024 revenues of 32.90m. This bettered the 31.50m consensus of the 2 analysts covering the company. This was 53.85% below the prior year's 3rd quarter results.
Average growth rate+5.59%
Genovis AB (publ.) had revenues for the full year 2023 of 158.23m. This was 54.54% above the prior year's results.
Average growth rate+29.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.